Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

NCT01294735 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrence of Solid Tumor
Glioblastoma Multiforme
Melanoma

Interventions

DRUG: MK-4827
DRUG: Temozolomide

Sponsor

Merck Sharp & Dohme LLC